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Current approaches to discovery-stage drug metabolism studies (pharmacokinetics, microsomal
stability, etc.) typically use triple-quadrupole–based approaches for quantitative analysis. This
necessitates the optimization of parameters such as Q1 and Q3 m/z values, collision energy, and
interface voltages. These studies detect only the specified compound and information about other
components, such as metabolites, is lost. The ability to perform full-scan acquisition for quantita-
tive analysis would eliminate the need for compound optimization while enabling the detection of
metabolites and other non-drug-related endogenous components. Such an instrument would have
to provide sensitivity, selectivity, dynamic range, and scan speed suitable for discovery-stage
quantitative studies. In this study, a prototype benchtop Orbitrap-based mass analyzer was used
to collect both quantitative and qualitative data from human microsomal incubation samples as
well as rat plasma from pharmacokinetic studies. Instrumental parameters such as scan speed,
resolution, and mass accuracy are discussed in relation to the requirements for a quantitative–
qualitative workflow. The ability to perform highly selective quantitative analysis while simulta-
neously characterizing metabolites from both in vitro and in vivo studies is discussed. (J Am Soc
Mass Spectrom 2009, 20, 1441–1450) © 2009 Published by Elsevier Inc. on behalf of American
Society for Mass SpectrometryThe widespread adoption of triple-quadrupolemass spectrometers for quantitative analysis inthe pharmaceutical industry has been a major
contributing factor to the reduced attrition ascribed to
poor pharmacokinetic properties [1, 2]. The high degree
of specificity provided by selected reaction monitoring
(SRM) is a recognized strength of triple-quadrupole–
based instruments, but it is also a limitation. Several
investigators have described the potential advantages of
using full-scan–based acquisition for quantitative analysis
using a variety of mass analyzers [3–8]. High among these
advantages is the ability to acquire information without
the need for specific methods to be developed beforehand.
For example, information about drug metabolites can be
mined from the data post-acquisition, leading to so-called
quantitative–qualitative workflows [9, 10]. Additionally,
information about nondrug components can also be in-
vestigated, whether to check for interferences or as a
readout to study endogenous biological processes.
Many quantitative workflows in early drug discov-
ery are focused on improving analytical throughput
using fast liquid chromatography–mass spectrometry
(LC-MS) approaches to screen large collections of com-
pounds [11–13]. A significant bottleneck in these work-
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doi:10.1016/j.jasms.2009.03.002flows is the time needed to develop the SRM methods
required for triple-quadrupole–based analysis. In cases
where compounds do not fragment favorably (either
non-specifically or not at all) the analyst is left with
limited options, especially when throughput is a key
requirement. The use of full-scan acquisition has the
potential to provide a solution to these problems.
For a full-scan approach to be acceptable in a discov-
ery environment it needs to provide sufficient selectiv-
ity, sensitivity, duty cycle, and dynamic range to ensure
that analysis is not compromised. In other words, the
benefits of ease of use and qualitative data acquisition
are not as important as having appropriate quantitative
capabilities. It is for these reasons that previous at-
tempts to use quantitative–qualitative workflows have
not been widely adopted. For example, full-scan anal-
ysis using a time-of-flight (TOF) mass analyzer lack
sufficient sensitivity and dynamic range [4]. Recent
improvements in TOF-based mass spectrometers hold
promise for true quantitative–qualitative workflows to
be developed [10].
A recently developed mass analyzer—the Orbitrap—
has many of the features required for a full-scan quan-
titative instrument [14]. It provides high mass resolu-
tion and mass accuracy, wide dynamic range, good
duty cycle, and good sensitivity. The first commercial
form of this instrument was a hybrid with a linear ion
trap coupled with the Orbitrap. Recently, a nonhybrid
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ized with improved performance relative to the first-
generation instrument [15]. This instrument is reduced
in both size and cost, relative to the first-generation
system, making it more accessible for use in routine
drug discovery screening applications. The system is
capable of generating fragmentation information in a
nonselective manner using a collision cell without pre-
cursor ion selection. In this way structural information
can be obtained on compounds of interest and fragment
ions can be used for confirmation in targeted analyses.
This report describes the performance of this new
benchtop Orbitrap mass spectrometer when applied to
specific applications (microsomal stability and plasma
drug level measurement) in a drug discovery environ-
ment. For the stability assay, relative quantitation of the
parent compound was used and metabolite information
was extracted post-acquisition. For plasma level mea-
surements, absolute quantitation of drug compound
using a within-run validation approach was used. The
full-scan data were mined for circulating metabolites in
plasma. The importance of chromatographic and mass
resolution for selectivity is discussed. In addition, the
availability of metabolite data from early discovery
assays and its potential impact on program timelines
are highlighted.
Experimental
Reagents and Materials
The synthesis of the cathepsin K inhibitors L-006235
and L-873724 has been previously reported [16, 17]. All
solvents were LC-MS grade or better. Formic acid and
acetonitrile were from Fisher Scientific (Ottawa, ON,
Canada) and LC-MS grade water was purchased from
VWR International (Quebec, QC, Canada). Columns
were purchased from Thermo Fisher Scientific (Missis-
sauga, ON, Canada) and analytical standards (verapamil,
labatelol, urapidil, loperamide, nefazadone, buspirone,
and haloperidol) were from Sigma. The analytical stan-
dards were dissolved in dimethylsulfoxide and com-
bined into a synthetic mixture containing 10 M of each
compound diluted in acetonitrile:water.
Animals
All procedures were approved by the Animal Care
Committee at the Merck Frosst Center for Therapeutic
Research according to the guidelines established by the
Canadian Council on Animal Care. Sprague–Dawley
rats (n  3) with an average mass of 300 g were used in
these studies.
Microsomal Incubations
Incubations with rat liver microsomes were conducted
at 37 °C with 0.25 mg/mL of microsomal protein in 0.1
M phosphate buffer, at a compound concentration of 1M, in the presence of 1 mM nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase and 1 mM
uridine 5=-diphosphoglucuronic acid (UDPGA) as co-
factors and 2 mM MgCl2 in a total volume of 500 L.
Aliquots were taken at multiple time points (5, 10, 15, 30,
and 60 min) quenched with 2 volumes of cold acetonitrile
containing labetalol (200 nM) as internal standard. Sam-
ples were centrifuged for 15 min at 3000g and the super-
natant was transferred to high-performance liquid chro-
matography (HPLC) vials for LC-MS analysis.
Plasma Collection and Preparation
Following the oral dosing of L-006235 or L-873724 (10
mg/kg, dose volume of 10 mL/kg with 1% methocel as
vehicle, n  3 rats), blood samples were collected at
0.25, 0.5, 1, 2, 4, and 6 h postdosing in addition to a
predose sample. Whole blood (400 L) was collected
into heparinized tubes and centrifuged (10 min, 1000g)
to separate plasma and red blood cells. Plasma (50 L)
was transferred into Eppendorf tubes quenched with
acetonitrile (150 L) containing labetalol (200 nM) as
internal standard and vortexed briefly to precipitate the
plasma proteins. Tubes were centrifuged at 4000 rpm
for 10 min to pelletize proteins and 120 L of superna-
tant was transferred to HPLC vials before analysis.
Instrument Layout Overview
The instrument used was a beta version of the Exac-
tive™ benchtop Orbitrap mass spectrometer. Samples
were introduced into the API source by either direct
infusion or a UHPLC system (Accela™). The source is
similar to the commercial source of a TSQ Quantum
Ultra™. Ions are transferred from the source through
four stages of differential pumping using radiofre-
quency (RF)-only multipoles into a curved RF-only
trapping quadrupole (the C-trap). In the C-trap ions are
accumulated and their energy is dampened using a bath
gas (nitrogen). Ions are then injected through three
further stages of differential pumping using a curved
lens system into the Orbitrap analyzer, where mass
spectra are acquired via image current detection. The
vacuum inside the Orbitrap mass analyzer is main-
tained below 1e-09 mbar.
Automatic Gain Control (AGC)
Automatic control of the number of ions in the Orbitrap
is performed by measuring the total ion charge using a
prescan and by calculating the ion injection time for the
analytical scan from this value. For very high mass scan
rates, the previous analytical scan is used as a prescan
to optimize the scan cycle time without compromising
automatic gain control. Ion gating is performed using a
fast split-lens setup that ensures the precise determina-
tion of the ion injection time.
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The incorporation of an additional collision cell allows
HCD (higher energy collision decomposition) experi-
ments to be performed. Ions are passed through the
C-trap into a multipole collision cell where they are
fragmented and stored. Subsequently, the HCD cell
voltages are ramped and ions are transferred back into
the C-trap from which they are injected into the Orbi-
trap for detection.
LC-MS Description
Initially the mass spectrometer was calibrated by infu-
sion of a standard test mixture of caffeine, MRFA
tetrapeptide, and Ultramark. All subsequent mass anal-
ysis was done using this initial mass calibration and no
internal calibration was used. Generic LC-MS condi-
tions were used throughout with no optimization of
source parameters or gradient conditions. Separations
were performed by injecting 25 L of sample onto a
2.1  100-mm Thermo Hypersil Gold C18 column with
1.9 micron particles. The chromatography was devel-
oped using a linear gradient from 2 to 95% acetonitrile
versus 0.1% formic acid in 5 min, at a flow rate of 500
L/min. Standard MS source conditions compatible
Figure 1. Comparison of (a) 10 Hz and (b) 1 Hz
(a) shows mass spectra taken from peak top and
top.with the flow rate were used (capillary temperature,
290 °C; sheath flow, 50; spray voltage, 3000 V; auxiliary
temperature, 400 °C). Scan speed was set depending on
the experiment and is described in more detail in the
following text. The collection of HCD data used a fixed
energy setting of 35 V.
Results and Discussion
Instrument Performance
To determine instrument performance characteristics in
terms of scan speed, resolution, and mass accuracy, a
synthetic mixture of drug molecules was prepared and
analyzed. The mixture was separated using the generic
LC conditions described earlier. In one experiment the
mass analyzer was set to acquire data at 10 Hz, the
fastest setting for the instrument. The resultant data
are shown in Figure 1a. The individual scans are
represented as dots on the chromatogram, indicating
that for peaks that are 3–4 s wide 30–40 points are
obtained across the peak. Extracted mass spectra are
shown as insets in Figure 1a. These spectra were taken
from the peak top and peak base, revealing that the
mass accuracy and resolution are preserved across the
full dynamic range of the chromatographic peak. There-
acquisition rates using the Exactive™. Insets in
tail. Inset in (b) shows spectra taken from peakdata
peak
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ion or a high abundant ion, mass accuracy and mass
resolution are maintained—this is important for accurate
quantification in full-scan mode.
A similar experiment was repeated using a scan
speed of 1 Hz, with the resulting data shown in Figure
1b. In this case fewer points (black dots) are obtained
across the chromatographic peak. However, the mass
resolution is greatly improved, as shown by the mass
spectrum in Figure 1b. The mass accuracy for the
instrument was found to be less than 3 ppmwhen using
external calibration. The data shown here indicate that,
for this mass analyzer, speed is obtained as a concession
to mass resolving power. Selectivity for specific ana-
lytes in complex matrices is obtained through mass
resolution when using full-scan instruments, so it is
important to understand the dependence of this param-
eter on scan speed when designing experiments.
Another important aspect of this instrument is the
capability to collect fragment ion information without
the need to select the precursor ion. Figure 2 shows data
collected when two scan functions are used for acqui-
sition, versus a single-function approach shown above.
This approach is similar to the high–low switching used
Figure 2. (a) MS and (c) HCD chromatograms f
spectrum extracted from peak labeled with arro
HCD mass spectrum from peak labeled with
fragment ions for verapamil.on QToF instruments for similar analysis [18]. In the
first scan, full MS data are acquired at 10 Hz by sending
the ions from the C-trap into the Orbitrap for mass
analysis (Figure 2a and b). In the second scan, the ions
are sent from the C-trap into the HCD cell, where they
are fragmented and then sent back to the C-trap and,
subsequently, to the Orbitrap for mass analysis (Figure
2c and d). By switching back and forth between these
two scans, two chromatograms are collected, one con-
taining the total ion count (TIC) for nonfragmented ions
(Figure 2a) and one for the fragmented ions (Figure 2c).
Qualitatively these two chromatograms are almost
identical. However, when one inspects the mass spectra
extracted from the chromatographic peaks the differ-
ences are apparent. In Figure 2b the mass spectrum
from the peak indicated by the arrow in Figure 2a is
shown. The main feature of the spectrum is the [M 
H] for verapamil. The corresponding spectrum (Figure
2d) taken from the peak indicated in Figure 2c shows a
rich fragment ion pattern for verapamil. These data are
collected with both high resolution and high mass
accuracy across the entire mass range and without loss
of the low mass ions because this fragmentation occurs
in the HCD cell and not in an ion trap. Although the
analysis of a mixture of 6 compounds. (b) Mass
(a) showing intact [M  H] for verapamil. (d)
in (c). Structure in (d) shows assignment ofor the
w in
arrow
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decreased, the sum of the ion intensity in Figure 2d
indicates that minimal losses occur by using HCD. This
is in contrast to the large scattering losses typically seen
when using in-source fragmentation to do similar type
experiments on single-stage mass analyzers. Because
this fragmentation is generated without precursor ion
selection, the ability to link fragment ions to a particular
precursor ion will depend on chromatographic resolu-
Figure 3. (a) Stability plot for compounds in
showing metabolic degradation. (b) Stability
metabolites detected using the Exactive. Inset in (
with structure assignment.tion or software algorithms for peak deconvolution or
both.
Microsomal Stability Samples
Analysis of microsomal stability samples is typically
performed on triple-quadrupole mass spectrometers to
have sufficient robustness, selectivity, and sensitivity.
Quantitation is done relative to a time-zero sample. This
ed in human microsomes over a time course
for verapamil with simultaneous plotting of
ows HCD spectrum for N-desmethyl metabolitecubat
plot
b) sh
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remaining and all subsequent time points are calculated
relative to this sample. As such, standard curves are not
used and the instrument response is assumed to be
linear across the range of concentrations detected (1
M) [19, 20]. When using a full-scan approach, no prior
method developed is required to determine multiple
Figure 4. Extracted ion chromatograms with th
(a) 3000 mDa, (b) 1000 mDa, (c) 500 mDa, (d)
obtained without loss of sensitivity using high-resolureaction monitoring (MRM) transitions for the com-
pounds of interest. Post-acquisition data processing
requires the monoisotopic mass of the compounds to
extract quantitative data.
Microsomal incubations for verapamil were ana-
lyzed with the Orbitrap mass analyzer using two scan
functions to acquire quantitative and qualitative infor-
e data file using decreasing extraction windows
mDa, and (e) 10 mDa. Improved selectivity ise sam
100tion full-scan data acquisition.
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grams (XICs) for the internal standard and verapamil
were generated (data not shown). Selectivity was pro-
vided by extracting the m/z values for each component
using a 5 ppm window (2.5 ppm) around the [M 
H]. At time  0 the peak area for 1 M verapamil was
about 4.9e6 and the peak area ratio with the internal
standard was 16.35. At time  30 min, the peak area
ratio was 0.076 and, assuming linear response, this
represents a concentration of around 4.5 nM verapamil.
When this experiment is repeated for a series of
compounds—as is typically done in a discovery screen-
ing laboratory to identify metabolically stable versus
unstable compounds—a plot such as shown in Figure
3a can be generated. In this case three compounds are
plotted, showing low to moderate stability. Providing
this type of information to project teams in early dis-
covery work can give the medicinal chemists some
information about which chemical series to pursue.
However, it would be of greater value if the structural
motif(s) leading to lack of metabolic stability could be
ascertained from this experiment.
In this case, HCD was acquired at the same time as
the MS data. By using knowledge of the fragmentation
pattern of the parent compound (Figure 2d), the data
can be mined post-acquisition for the presence of me-
tabolites. Equivalent to performing a precursor ion scan
in software, fragment ion masses can be extracted from
the HCD data to see whether other peaks are present
that may correspond to metabolites. In addition, the MS
data can be mined with a list of expected metabolite
masses. Moreover, fractional mass filtering can be used
as another tool to process this high mass resolution
dataset [18, 21]. For this current study, data processing for
metabolite identification was done manually and, in the
future, software tools will be needed to automate this
process if these workflows are to be widely adopted.
Found metabolites can be plotted relative to the
parent, with the caveat that their response factors may
be different from those of the parent molecule. In a
discovery environment this is an acceptable risk, given
the benefit derived from knowing sites of metabolism.
A plot of parent and metabolites can be generated as
shown in Figure 3b. An example of the HCD for the
N-desmethyl metabolite is shown as an inset in Figure
3b. Information about location of metabolic soft spots
becomes very powerful in the hands of medicinal
chemists because they can now modify their synthetic
strategy to target the known metabolic soft spots, rather
than guessing blindly at what modifications to make.
Quantification of Drugs in Plasma
Quantitative analysis of target compounds in a complex
biological matrix such as plasma requires both selectiv-
ity and sensitivity. In the case of triple-quadrupole
instruments, selectivity is obtained by using tandem
mass spectrometry and sensitivity is provided by the
high duty cycle. Full-scan acquisition on a quadrupolemass filter sacrifices both sensitivity and selectivity [7].
For mass analyzers such as time of flight and Orbitrap,
sensitivity and selectivity are not mutually exclusive
parameters. This is illustrated in Figure 4 for the anal-
ysis of a rat plasma sample from a pharmacokinetic
study. Data were collected at a resolution setting of
30,000 full-width half-maximum for these plasma sam-
ples because it was found that at R  10,000 the
compound was not completely resolved from endoge-
nous interferences. The chromatograms were generated
by extracting m/z 482.1720 (L-873724) using decreasing
extraction window widths around the mass of interest.
When a large mass extraction window is used (Figure
4a and b) selectivity is poor and accurate quantification
is not possible. As the extraction window is narrowed
from 500 mDa (Figure 4c) down to 10 mDa (Figure 4e),
the selectivity is improved such that the target com-
pound can be accurately quantified (see the following
text). The chromatograms are plotted with the same
Figure 5. Comparison of triple-quadrupole quantitative analysis
with data obtained from the Exactive. (a) L-006235 and (b)
L-873724.
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not lost with decreasing extraction window. It is impor-
tant to note that mass accuracy must be maintained as
the extraction window is decreased; otherwise, the
signal would be lost by falling outside the narrow
window. It is thus important to have a mass analyzer
that maintains mass accuracy over time and over a wide
dynamic range of signal; otherwise, accurate quantifi-
cation will not be possible.
To assess the absolute quantitative capabilities of the
system, it was compared with results obtained from
triple-quadrupole mass spectrometry. Duplicate stan-
dard curves and four levels of quality control samples
in triplicate were used to generate the quantitative
results of the unknown samples. The resulting pharma-
cokinetic (PK) curves are plotted in Figure 5. Although
the absolute sensitivity of the Orbitrap system is nearly
tenfold less than that of the triple quadrupole for the
compounds used in this study, this has no effect on the
PK curves. As shown in Figure 5, the calculated con-
centrations for the two compounds in plasma are equiv-
alent within the error of the measurement, independent
of mass analyzer. We are therefore confident that we
can use a high-resolution full-scan instrument to do
absolute quantitative analysis.
Because the data were acquired using full scan,
post-acquisition processing for metabolites or other
compounds of interest was possible. Figure 6 shows a
plot of peak area ratio versus time for L-873724 and a
series of metabolites identified in rat plasma. Absolute
quantification was not possible in this case because
Figure 6. Plot of peak area ratios for L-873724 a
course for circulating metabolites. This data we
data files.standards for the metabolites were not available. One
must thus be careful in interpreting data because it is
assumed, in this case, that the metabolites have a
response factor similar to that of the parent molecule.
Although this may be true in many cases, it is not
always so [22, 23]. However, even with these caveats,
the data are useful in a discovery environment.
In this case, two metabolites were found to have
higher exposure than that of the parent compound.
Even though obtaining this information is possible by
subsequent analysis of plasma samples for metabolites,
this type of experiment is not routinely done because it
is time consuming and labor intensive. By using full-
scan acquisition, the data are collected up front and,
when appropriate, the data file can be processed to look
for metabolites. In effect, the metabolite data are col-
lected for “free” and can be mined at a later date.
Knowing the sites of metabolism in early discovery
gives the chemist the option to block them during lead
optimization. Determining this information only in de-
velopment could result in lengthened timelines and
increased costs. In the case of L-873724, the metabolites
detected in plasma are shown in Scheme 1. Blocking the
two main sites of metabolism on L-873724 led to the
discovery of odanacatib, a potent and highly selective
cathepsin K inhibitor [17].
Conclusions
The use of high-resolution and high mass accuracy data
acquisition offers the potential for a fundamental shift
etabolites found in rat plasma showing the time
nerated post-acquisition by mining of the rawnd m
re ge
3724
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covery. This type of data acquisition—when coupled
with sufficient sensitivity, dynamic range, and duty
cycle—opens new opportunities for analytical labora-
tories. The data shown here using the nonhybrid Orbi-
trap suggest that this type of mass analyzer will be
capable of a quantitative–qualitative workflow. It
should be emphasized that high resolution (20,000)
and stability of mass accuracy for every peak in every
scan are critical to the successful use of full-scan data for
quantitative determinations. Full-scan data allow for
many possibilities for analysis and post-acquisition
processing that are not available when doing targeted
analysis. These include, for example, the ability to
acquire without the need for SRM method develop-
ment, dynamic range extension by using isotope data,
quantification using HCD data, metabolite identifica-
tion, and analysis of endogenous compounds. Given the
current need for improved success rates in drug discov-
ery and perceived lack of innovation [24], bringing
together quantitative and qualitative analyses may pro-
vide a capability that opens new doors. For this workflow
to be successful, development of software tools that take
advantage of full-scan datasets will be required.
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